Analysis of quality of life in patients with gonarthrosis after application of autologous leukocyte-rich and leukocyte-poor platelet-rich plasma

Home/2020, Vol. 8, No. 2/Analysis of quality of life in patients with gonarthrosis after application of autologous leukocyte-rich and leukocyte-poor platelet-rich plasma

Cell and Organ Transplantology. 2020; 8(2):99-105.
DOI: 10.22494/cot.v8i2.112

Analysis of quality of life in patients with gonarthrosis after application of autologous leukocyte-rich and leukocyte-poor platelet-rich plasma

Goliuk Ye.¹, Pschenychny T.¹, Ostapenko T.², Yavorovska V.¹, Magomedov O.¹

  • ¹State Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • ²Ukrainian Scientific Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of Ministry of Health of Ukraine, Kyiv, Ukraine

Abstract

In recent years, there is a growing interest in the application of regenerative medicine methods in the treatment of degenerative injuries of the musculoskeletal system. Knee osteoarthritis (gonarthrosis) is one of the most common reasons for visiting orthopedic surgeons to patients.
The purpose of the study was to evaluate the quality of life in patients with different stages of gonarthrosis after application of leukocyte-rich platelet-rich plasma (LR-PRP) and leukocyte-poor platelet-rich plasma (LP-PRP).
Materials and methods. The results of the treatment of 48 patients with gonarthrosis grades 1-3 according to Kellgren-Lawrence after intra-articular injection of LR-PRP or LP-PRP were compared. The quality of life questionnaires were used: visual analogue scale, Lysholm Knee Score and Oxford Knee Score before treatment, after the first injection, every 2 weeks before the end of treatment and every 3 months for 1 year.
Results. Evaluation of the treatment results obtained at stages 1 and 2 of knee osteoarthritis showed a positive result for both groups of patients during 12 months of follow-up and at stage 3 a significant improvement was achieved for up to 6 months. There was no significant difference between the results of LR-PRP and LP-PRP injections for 9-12 months. After using LP-PRP treatment, the dynamics of quality of life during the year was stepless and more steady, without periods of regression while for LR-PRP injections was a clear significant short-term reduction in the treatment effect for about 6 months, compared to both baseline and values of the previous period at 1 and 2 stages gonarthrosis with further improvement and a stable positive effect for up to 12 months.
Conclusions. The application of platelet-rich plasma improved the quality of life for 12 months in patients with stage 1-2 gonarthrosis and for 6 months at stage 3. The obtained positive results substantiate the need for further research to determine the prospects for the application of platelet-rich plasma in the complex treatment of knee osteoarthritis compared to other methods.

Key words: regenerative medicine; platelet-rich plasma; gonarthrosis; quality of life

Full Text PDF (preprint)

1. Assirelli E., Filardo G. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg. Sports. Traumatol. Arthrosc. 2015;23(6):2690-2703. doi: 10.1007/s00167-014-3113-3
https://doi.org/10.1007/s00167-014-3113-3
PMid:24942296 PMCid:PMC4541703
2. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33(5):657-70. doi: 10.1016/j.immuni.2010.11.011. PMID: 21094463.
https://doi.org/10.1016/j.immuni.2010.11.011
PMid:21094463
3. Caplan A., Correa D. PDGF in bone formation and regeneration: New Insights into a Novel Mechanism Involving MSCs. J. Orthop. Res. 2011:1795-1803. DOI: 10.1002/jor.21462
https://doi.org/10.1002/jor.21462
PMid:21618276
4. Chubinskaya S, Kuettner KE, Cole AA. Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints. Lab Invest. 1999;79(12):1669-77.
5. DeLong J. M., Russell R. P., Mazzocca A. D.. Platelet-rich plasma: the PAW classification system. Arthroscopy: the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2012. 28(7), 998-1009. DOI:10.1016/j.arthro.2012.04.148
https://doi.org/10.1016/j.arthro.2012.04.148
PMid:22738751
6. Dohan Ehrenfest D. M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends in biotechnology. 2009; 27(3):158-167. DOI:10.1016/j.tibtech.2008.11.009
https://doi.org/10.1016/j.tibtech.2008.11.009
PMid:19187989
7. Duif C., Vogel T., Topcuoglu F., Spyrou G., von Schulze Pellengahr C., Lahner M. Does intraoperative application of leukocyte-poor platelet-rich plasma during arthroscopy for knee degeneration affect postoperative pain, function and quality of life? A 12-month randomized controlled double-blind trial. Archives of orthopaedic and trauma surgery. 2015. 135(7):971-977. DOI: 10.1007/s00402-015-2227-5)
https://doi.org/10.1007/s00402-015-2227-5
PMid:25957981
8. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114(6):1502-1508. DOI:10.1097/01.prs.0000138251.07040.51
https://doi.org/10.1097/01.PRS.0000138251.07040.51
PMid:15509939
9. Filardo G, Kon E, DI Matteo B, DI Marino A, Sessa A, Merli ML, Marcacci M. Leukocyte-poor PRP application for the treatment of knee osteoarthritis. Joints. 2014;1(3):112-20. DOI:10.11138/jts/2013.1.3.112
https://doi.org/10.11138/jts/2013.1.3.112
PMid:25606520
10. Filardo G., Previtali D., Napoli F., Candrian C., Zaffagnini S., Grassi A. (2020). PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Cartilage, 1947603520931170. DOI: 10.1177/1947603520931170)
https://doi.org/10.1177/1947603520931170
PMid:32551947
11. Fitzpatrick J., Bulsara M. K., McCrory P. R., Richardson M. D., Zheng M. H. Analysis of Platelet-Rich Plasma Extraction: Variations in Platelet and Blood Components Between 4 Common Commercial Kits. Orthopaedic journal of sports medicine. 2017;5(1). DOI:10.1177/2325967116675272
https://doi.org/10.1177/2325967116675272
PMid:28210651 PMCid:PMC5302100
12. Furman M.I., Barnard M.R., Krueger L.A., Fox M.L., Shilale E.A., Lessard D.M. et al. Circulating Monocyte-platelet aggregates are an early marker of acute myocardial infarction.. J. Am. Coll. Cardiol. 2001;38:1002-6. DOI: 10.1016/s0735-1097(01)01485-1
https://doi.org/10.1016/S0735-1097(01)01485-1
13. Htun P., Fateh-Moghadam S., Tomandl B., Klinger K., Stellos K., Garlichs C. et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia.. Stroke. 2006;37:2283-7. DOI: 10.1161/01.STR.0000236638.75591.61
https://doi.org/10.1161/01.STR.0000236638.75591.61
PMid:16888273
14. Joseph J.E., Harrison P., Mackie I.J., Isenberg D.A. Increased circulating plateletleucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Brithsh J. Haematol. 2001;115:451-9. DOI: 10.1046/j.1365-2141.2001.03101.
https://doi.org/10.1046/j.1365-2141.2001.03101.x
PMid:11703349
15. Kikuchi N., Yoshioka T., Taniguchi Y. et al. Optimization of leukocyte-poor platelet-rich plasma preparation: a validation study of leukocyte-poor platelet-rich plasma obtained using different preparer, storage, and activation methods. J Exp Ortop. 2019;6(24). DOI:10.1186/s40634-019-0190-8
https://doi.org/10.1186/s40634-019-0190-8
PMid:31161535 PMCid:PMC6546777
16. Kobayashi Y., Saita Y., Nishio H. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016;21(5):683-689. DOI: 10.1016/j.jos.2016.07.009
https://doi.org/10.1016/j.jos.2016.07.009
PMid:27503185
17. Kennedy M.I., Whitney K., Evans T., LaPrade R.F. Platelet-rich plasma and cartilage repair. Curr Rev Musculoskelet Med.- 2018;11(4):573-582. DOI: 10.1007/s12178-018-9516
https://doi.org/10.1007/s12178-018-9516-x
PMid:30203333 PMCid:PMC6220001
18. Lana J. F., Huber S. C., Purita J., Tambeli C. H., Santos G. S., Paulus C., Annichino-Bizzacchi J. M. Leukocyte-rich PRP versus leukocyte-poor PRP – The role of monocyte/macrophage function in the healing cascade. J Clin Orthop Trauma. 2019;Suppl 1:S7-S12. https://doi.org/10.1016/j.jcot.2019.05.008
https://doi.org/10.1016/j.jcot.2019.05.008
PMid:31700202 PMCid:PMC6823808
19. Leonidou A., Lepetsos P., Mintzas M., Kenanidis E. Inducible nitric oxide synthase as a target for osteoarthritis treatment. Expert Opin Ther Targets. 2018;22(4):299-318. DOI: 10.1080/14728222.2018.1448062
https://doi.org/10.1080/14728222.2018.1448062
PMid:29504411
20. Lucarelli E., Beccheroni A., Donati D., Sangiorgi L., et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials. 2003. 24(18):3095-3100. https://doi.org/10.1016/s0142-9612(03)00114-5).
https://doi.org/10.1016/S0142-9612(03)00114-5
21. Meeson R., Sanghani-Keri A., Coathup M. VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing. J Orthop Res. 2019;37(6):1294-1302. DOI: 10.1002/jor.24164
https://doi.org/10.1002/jor.24164
PMid:30345545 PMCid:PMC6563072
22. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol. 1996;28:345-53. DOI: 10.1016/0735-1097(96)00164-7
https://doi.org/10.1016/0735-1097(96)00164-7
23. Oltulu I., Korkmaz O., Isyar M., Kara A., Bulbul A. M., Mahirogulları M. Does the Difference in Leukocyte Concentration of PRP Affect the Short-Term Follow-Up Results in Cases Diagnosed with Early Stage Knee Osteoarthritis? Serbian Journal of Experimental and Clinical Research. 2019. DOI:10.2478/sjecr-2019-0010).
https://doi.org/10.2478/sjecr-2019-0010
24. Ott I., Neumann F.J., Gawaz M., Schmitt M., Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation J. 1996;94:1239-46. DOI: 10.1161/01.cir.94.6.1239
https://doi.org/10.1161/01.CIR.94.6.1239
PMid:8822975
25. Pifer M.A., Maerz T., Baker K.C., Anderson K. Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts. Am J Sports Med. 2014; 42(5):1211-1218. DOI:10.1177/0363546514524710.
https://doi.org/10.1177/0363546514524710
PMid:24627579
26. Singh M.V., Davidson D.C., Kiebala M., Maggirwar S.B. Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. J. Virol. Methods. 2012; 181(2):170-6. doi: 10.1016/j.jviromet.2012.02.005
https://doi.org/10.1016/j.jviromet.2012.02.005
PMid:22387340 PMCid:PMC3322263
27. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285-94. doi: 10.1016/j.immuni.2005.01.011. PMID: 15780986.
https://doi.org/10.1016/j.immuni.2005.01.011
PMid:15780986
28. Xie X., Zhang C., Tuan R.S. Biology of platelet-rich plasma and its clinicalapplication in cartilage repair. Arthritis Res Ther. 2014;16(1):204. DOI: 10.1186/ar4493
https://doi.org/10.1186/ar4493
PMid:25164150 PMCid:PMC3978832
29. Yin W.J., Xu H.T., Sheng J.G. Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in treating rabbit knee osteoarthritis. Med Sci Monit.- 2016;22):1280-90. doi: 10.12659/msm.898218.
https://doi.org/10.12659/MSM.898218
PMid:27086145 PMCid:PMC4837928
30. Yin W., Xin Q., Zhang Y. Advantages of pure platelet rich plasma compared with leukocyte and platelet richplasma in promoting repair of bone defects. J Transl Med. 2016;14:73. DOI: 10.1186/s12967-016-0825-9
https://doi.org/10.1186/s12967-016-0825-9
PMid:26980293 PMCid:PMC4792107
31. Yoshida R., Murray M. M. Peripheral blood mononuclear cells enhance the anabolic effects of platelet-rich plasma on anterior cruciate ligament fibroblasts. J Orthop Res. 2013;31(1):29-34. https://doi.org/10.1002/jor.22183
https://doi.org/10.1002/jor.22183
PMid:22767425 PMCid:PMC3469725
32. Wang S.Z., Fan W.M., Jia J. Is exclusion of leukocytes from platelet-rich plasma (PRP) a better choice for early intervertebral disc regeneration?. Stem Cell Res Ther. 2018;9(1):199. DOI: 10.1186/s13287-018-0937-7
https://doi.org/10.1186/s13287-018-0937-7
PMid:30021649 PMCid:PMC6052621
33. Wojdasiewicz P., Poniatowski Ł.A., Szukiewicz D. The Role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthrit is mediators. Inflamm. 2014;2014:561459. DOI: 10.1155/2014/561459
https://doi.org/10.1155/2014/561459
PMid:24876674 PMCid:PMC4021678
34. Wong V.W., Wan D.C., Gurtner G.C., Longaker M.T. Regenerative surgery: tissue engineering in general surgical practice. World Journal of Surgery. 2012;36(10):2288-2299. DOI:10.1007/s00268-012-1710-1.
https://doi.org/10.1007/s00268-012-1710-1
PMid:22777416

Goliuk Ye, Pschenychny T, Ostapenko T, Yavorovska V, Magomedov O. Analysis of quality of life in patients with gonarthrosis after application of autologous leukocyte-rich and leukocyte-poor platelet-rich plasma. Cell and Organ Transplantology. 2020; 8(2):99-105. doi:10.22494/cot.v8i2.112

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.